Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer

Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel

(2022) Giampaolo Bianchini et al.   Cancers

163O Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)

(2022) G. Curigliano et al.   ANNALS OF ONCOLOGY

Abstract OT1-12-04: A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)

(2022) Nadia Harbeck et al.   CANCER RESEARCH

Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management

(2022) Sandra M. Swain et al.   CANCER TREATMENT REVIEWS

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

(2022) Javier Cortés et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment

(2022) P. Conte et al.   ESMO Open

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

(2022) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

92O Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)

(2021) C.A. Powell et al.   ANNALS OF ONCOLOGY

279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)

(2021) C. Saura Manich et al.   ANNALS OF ONCOLOGY

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

(2021) Bob T. Li et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates

(2021) Paolo Tarantino et al.   JAMA Oncology

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

(2020) Shanu Modi et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

(2020) Kohei Shitara et al.   NEW ENGLAND JOURNAL OF MEDICINE

Scalp cooling to prevent chemotherapy-induced alopecia

(2020) Giselle de Barros Silva et al.   ANAIS BRASILEIROS DE DERMATOLOGIA

Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment

(2020) A. Fabi et al.   ANNALS OF ONCOLOGY

Antiemetics: ASCO Guideline Update

(2020) Paul J. Hesketh et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of Chemotherapy-Induced Nausea and Vomiting with Trastuzumab Deruxtecan: A Case Series

(2020) Matthew Stankowicz et al.   Breast Care

Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆

(2020) M.E. Lacouture et al.   ANNALS OF ONCOLOGY

The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy

(2019) Takashi Nakada et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study

(2019) Kohei Shitara et al.   LANCET ONCOLOGY

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

(2019) Kenji Tamura et al.   LANCET ONCOLOGY

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

(2019) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Scalp Hypothermia for Preventing Alopecia During Chemotherapy. A Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2018) Hope S. Rugo et al.   Clinical Breast Cancer

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

(2017) Toshihiko Doi et al.   LANCET ONCOLOGY

Management of febrile neutropaenia: ESMO Clinical Practice Guidelines†

(2016) J. Klastersky et al.   ANNALS OF ONCOLOGY

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

(2016) F. Roila et al.   ANNALS OF ONCOLOGY

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

(2016) Y. Ogitani et al.   CLINICAL CANCER RESEARCH

2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy

(2016) Jørn Herrstedt et al.   SUPPORTIVE CARE IN CANCER

Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review

(2015) K. Jordan et al.   ANNALS OF ONCOLOGY

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

(2015) Thomas J. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Expression of Cathepsin L: A Novel Independent Prognostic Marker of Worse Outcome in Hepatocellular Carcinoma Patients

(2014) Jian Ruan et al.   PLoS One

Cathepsin B: Multiple roles in cancer

(2014) Neha Aggarwal et al.   Proteomics Clinical Applications

Pathobiology of chemotherapy-induced hair loss

(2013) Ralf Paus et al.   LANCET ONCOLOGY

Anticipatory nausea and vomiting

(2010) Joseph A. Roscoe et al.   SUPPORTIVE CARE IN CANCER